<- Go Home
Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Market Cap
$425.9M
Volume
2.4M
Cash and Equivalents
$177.9M
EBITDA
-$172.1M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$6.42
52 Week Low
$1.73
Dividend
N/A
Price / Book Value
2.70
Price / Earnings
-1.96
Price / Tangible Book Value
2.70
Enterprise Value
$229.3M
Enterprise Value / EBITDA
-1.34
Operating Income
-$172.4M
Return on Equity
109.83%
Return on Assets
-56.92
Cash and Short Term Investments
$200.4M
Debt
$3.8M
Equity
$158.0M
Revenue
N/A
Unlevered FCF
N/A
Sector
Biotechnology
Category
N/A